afatinib + ruxolitinib

Afatinib + ruxolitinib is an investigational combination therapy consisting of two small molecule inhibitors. Afatinib is an irreversible inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, while ruxolitinib is a selective inhibitor of Janus kinase 1 and 2 (JAK1/2). This combination has been studied in patients with EGFR-mutant non-small cell lung cancer (NSCLC) who have developed resistance to prior EGFR-TKI therapies. The rationale for combining these agents is to overcome acquired resistance mechanisms in NSCLC by simultaneously targeting both the EGFR and JAK-STAT signaling pathways. Clinical studies have shown that this regimen is tolerated, with modest clinical activity observed in this patient population[1][2].